Last Updated: November 13, 2026

Vanda Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for VANDA PHARMS INC

VANDA PHARMS INC has six approved drugs.

There are fifty-five US patents protecting VANDA PHARMS INC drugs.

Summary for Vanda Pharms Inc

US Patents:	55
Tradenames:	6
Ingredients:	5
NDAs:	6

Drugs and US Patents for Vanda Pharms Inc

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes	11,566,011	⤷ Start Trial	Y	Y		⤷ Start Trial
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-005	Feb 20, 2026		RX	Yes	No	9,072,742	⤷ Start Trial				⤷ Start Trial
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-006	Feb 20, 2026		RX	Yes	No	9,157,121	⤷ Start Trial				⤷ Start Trial
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021		RX	Yes	No	12,336,980	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Vanda Pharms Inc

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-003	May 6, 2009	RE39198	⤷ Start Trial
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-006	May 6, 2009	RE39198	⤷ Start Trial
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021	9,000,018	⤷ Start Trial
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-006	May 6, 2009	9,138,432	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for VANDA PHARMS INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	20 mg	➤ Subscribe	2018-01-31
➤ Subscribe	Tablets	1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, & 12 mg	➤ Subscribe	2013-05-06
➤ Subscribe	Capsules	20 mg	➤ Subscribe	2018-01-31

International Patents for Vanda Pharms Inc Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Mexico	2015007909	⤷ Start Trial
Russian Federation	2014134552	⤷ Start Trial
South Korea	20110071133	⤷ Start Trial
European Patent Office	4415699	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Vanda Pharms Inc Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3256125	2290019-5	Sweden	⤷ Start Trial	PRODUCT NAME: PONESIMOD AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT. REG. NO/DATE: EU/1/21/1550 20210521; FIRST REG.: GE EU/1/21/1550 20210521
3256125	PA2022505,C3256125	Lithuania	⤷ Start Trial	PRODUCT NAME: PONEZIMODAS; REGISTRATION NO/DATE: EU/1/21/1550 20210519
3256125	22C1021	France	⤷ Start Trial	PRODUCT NAME: PONESIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1550 20210521
3256125	C202230019	Spain	⤷ Start Trial	PRODUCT NAME: PONESIMOD: (R)-5-(3-CLORO-4-(2,3-DIHIDROXIPROPOXI)-BENZO(Z)IDEN)-2-((Z)-PROPILIMINO)-3-O-TOLIL-TIAZOLIDIN-4-ONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1550; DATE OF AUTHORISATION: 20210519; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1550; DATE OF FIRST AUTHORISATION IN EEA: 20210519
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Vanda Pharms Inc

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.